Single User
£3750
PDF
42 pages

Acute Respiratory Distress Syndrome (ARDS) Forecast in 11 Major Markets 2017-2027


Acute respiratory distress syndrome (ARDS) is an acute severe lung disease. It most often develops in those admitted to an intensive care unit (ICU), and can be caused by a number of 'triggers', which include trauma to the lungs and pneumonia. ARDS is characterised by wide-spread diffuse injury to the alveolar-capillary membrane, pulmonary inflammation and increased pulmonary vascular permeability. This results in protein-rich non-cardiogenic pulmonary oedema, refractory hypoxaemia and acute respiratory failure.

This report provides the current prevalent population for Acute Respiratory Distress Syndrome across 11 Major Markets (USA, France, Germany, Italy, Spain, UK, Japan, Brazil, Poland, Turkey and Netherlands) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of ARDS have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

These common ARDS signs and symptoms include:

  • Severity as classified by the Berlin definition
  • Aetiology of the lung injury

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global ARDS market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of ARDS and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on ARDS prevalent population.
  • Identify sub-populations within ARDS which require treatment.
  • Gain an understanding of the specific markets that have the largest number of ARDS patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Disease Prognosis & Clinical Course
  • Methodology for quantification of patient numbers
  • Incidence of ARDS in Hospital Admissions to the ICU
  • Features of ARDS Patients
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Figures
  • Total Hospital Admissions within the USA, compared to the total number of admissions to ICU and the total number of ARDS clinically diagnosed cases
List of Tables
  • Incidence of ARDS in hospital admissions to the ICU, total (000s)
  • Incidence of ARDS in hospital admissions to the ICU, males (000s)
  • Incidence of ARDS in hospital admissions to the ICU, females (000s)
  • Severity of ARDS, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Hospital admissions by 5-yr age cohort, total (000s)
  • USA Hospital admissions by 5-yr age cohort, total (000s)
  • Poland Hospital admissions by 5-yr age cohort, total (000s)
  • Poland Hospital admissions by 5-yr age cohort, total (000s)
  • France Hospital admissions by 5-yr age cohort, total (000s)
  • France Hospital admissions by 5-yr age cohort, total (000s)
  • Germany Hospital admissions by 5-yr age cohort, total (000s)
  • Germany Hospital admissions by 5-yr age cohort, total (000s)
  • Italy Hospital admissions by 5-yr age cohort, total (000s)
  • Italy Hospital admissions by 5-yr age cohort, total (000s)
  • Spain Hospital admissions by 5-yr age cohort, total (000s)
  • Spain Hospital admissions by 5-yr age cohort, total (000s)
  • UK Hospital admissions by 5-yr age cohort, total (000s)
  • UK Hospital admissions by 5-yr age cohort, total (000s)
  • Brazil Hospital admissions by 5-yr age cohort, total (000s)
  • Brazil Hospital admissions by 5-yr age cohort, total (000s)
  • Japan Hospital admissions by 5-yr age cohort, total (000s)
  • Japan Hospital admissions by 5-yr age cohort, total (000s)
  • Turkey Hospital admissions by 5-yr age cohort, total (000s)
  • Turkey Hospital admissions by 5-yr age cohort, total (000s)
  • Netherlands Hospital admissions by 5-yr age cohort, total (000s)
  • Netherlands Hospital admissions by 5-yr age cohort, total (000s)
Brazil, France, Germany, Italy, Japan, Netherlands, Poland, Spain, Turkey, United Kingdom, United States of America